proxyvotesnow.com

Home › Companies › ARCUS BIOSCIENCES INC. › 2023-2024

ARCUS BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARCUS BIOSCIENCES INC.’s Form 8-K, filed 2024-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 214Asset managers
  • 1,450Fund votes
  • 2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARCUS BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARCUS BIOSCIENCES INC.

These tallies are ARCUS BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARCUS BIOSCIENCES INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Kathryn Falberg 66,352,943---- 10,783,2158,822,193 Majority: yes
Elect Director: Linda Higgins 61,694,808---- 15,441,3508,822,193 Majority: yes
Elect Director: Terry Rosen 67,130,968---- 10,005,1908,822,193 Majority: yes
Proposal 2: The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024: 84,330,5861,242,487385,278 ---- Majority: yes
Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: 74,230,2762,863,26042,662 --8,822,193 Majority: yes

Source: ARCUS BIOSCIENCES INC., Form 8-K, filed with the SEC on 2024-06-06 — read the filing on EDGAR.

How asset managers voted at the ARCUS BIOSCIENCES INC. 2023-2024 meeting

Each item below shows how the 214 asset managers that disclosed a ARCUS BIOSCIENCES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement.

COMPENSATIONMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 74,230,276AGAINST: 2,863,260

ARCUS BIOSCIENCES INC.’s own tally for this item (“Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 74,230,276 for, 2,863,260 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 90,900,000 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).

The 213 asset managers below cast 95% of the shares they voted on this item FOR (49,018,246 for, 2,384,112 against).

FOR 95%
FOR: 49,018,246 (95.3%)AGAINST: 2,384,112 (4.6%)ABSTAIN: 10,389 (0.0%)NOT VOTED: 2,930 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclose” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity10,552,9590 00For
State Street7,995,42445,077 00For
BlackRock6,562,3127,194 00For
Vanguard4,796,7790 00For
Woodline Partners LP2,498,9940 00For
Point721,759,1010 00For
Dimensional1,361,1040 00For
GEODE CAPITAL MANAGEMENT, LLC1,151,0100 00For
AMERIPRISE FINANCIAL INC1,053,1520 00For
AllianceBernstein997,4620 00For
Charles Schwab962,5610 00For
SUVRETTA CAPITAL MANAGEMENT, LLC957,2990 00For
Decheng Capital LLC869,7900 00For
BNP Paribas Asset Management Holding S.A.0732,497 00Against
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Laurion Capital Management LP502,1230 00For
Northern Trust439,3102,016 00For
Delaware/Macquarie379,1000 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST379,1000 00For
Equitable336,9070 00For
PRINCIPAL GLOBAL INVESTORS288,3920 00For
MELLON INVESTMENTS Corp283,7460 00For
NORDEA INVESTMENT MANAGEMENT AB0259,372 00Against
MUTUAL FUND SERIES TRUST240,0000 00For
UBS19233,242 00Against

Showing the 25 largest of 213 asset managers. See all 213 in the interactive database.

2. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 84,330,586AGAINST: 1,242,487

ARCUS BIOSCIENCES INC.’s own tally for this item (“Proposal 2: The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending”): 84,330,586 for, 1,242,487 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 90,900,000 outstanding shares: 93% for, 1% against (94% of the company cast a for/against vote).

The 76 asset managers below cast 98% of the shares they voted on this item FOR (23,785,827 for, 546,640 against).

FOR 98%
FOR: 23,785,827 (97.7%)AGAINST: 546,640 (2.2%)ABSTAIN: 10,214 (0.0%)
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,844,3280 00For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,520,0865,286 00For
Dimensional1,184,5660 00For
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Charles Schwab0468,738 00Against
Delaware/Macquarie379,1000 00For
Equitable336,9070 00For
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust175,2800 00For
Columbia Threadneedle155,7870 00For
Victory Capital139,7270 00For
Jackson National136,4380 00For
TIAA125,2900 00For
ALPS ETF Trust64,0900 00For
BNY Mellon62,0550 00For
ProShares61,7390 00For
Principal60,7150 00For
Invesco58,0860 00For
American Century57,8980 00For
Prudential/PGIM56,2230 00For
MFS56,1740 00For
Lincoln Financial53,1380 00For
Thrivent46,4290 00For

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

3. Election of Directors: Kathryn Falberg

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%14%
FOR: 66,352,943WITHHELD: 10,783,215

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Kathryn Falberg”): 66,352,943 for, 10,783,215 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 90,900,000 outstanding shares: 73% for, 12% withheld (85% of the company cast a for/withheld vote).

The 76 asset managers below cast 100% of the shares they voted on this item FOR (20,673,016 for, 0 against).

FOR 85%ABSTAIN 15%
FOR: 20,673,016 (84.9%)ABSTAIN: 3,669,665 (15.1%)
Largest asset managers voting on “Election of Directors: Kathryn Falberg” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,806,9460 37,3820For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,475,3330 50,0390For
Dimensional00 1,184,5660Abstain
AB DISCOVERY GROWTH FUND, INC.00 551,1750Abstain
Charles Schwab468,7380 00For
Delaware/Macquarie00 379,1000Abstain
Equitable82,9990 253,9080Abstain
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 175,2800Abstain
Columbia Threadneedle155,7870 00For
Victory Capital00 139,7270Abstain
Jackson National00 136,4380Abstain
TIAA125,2900 00For
ALPS ETF Trust00 64,0900Abstain
BNY Mellon00 62,0550Abstain
ProShares00 61,7390Abstain
Principal00 60,7150Abstain
Invesco58,0860 00For
American Century00 57,8980Abstain
Prudential/PGIM56,2230 00For
MFS00 56,1740Abstain
Lincoln Financial44,4000 8,7380For
Thrivent00 46,4290Abstain

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

4. Election of Directors: Linda Higgins, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%
FOR: 61,694,808WITHHELD: 15,441,350

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Linda Higgins”): 61,694,808 for, 15,441,350 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 90,900,000 outstanding shares: 68% for, 17% withheld (85% of the company cast a for/withheld vote).

The 76 asset managers below cast 100% of the shares they voted on this item FOR (17,051,197 for, 0 against).

FOR 70%ABSTAIN 30%
FOR: 17,051,197 (70.0%)ABSTAIN: 7,291,484 (30.0%)
Largest asset managers voting on “Election of Directors: Linda Higgins, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,806,9460 37,3820For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street35,9430 3,489,4290Abstain
Dimensional00 1,184,5660Abstain
AB DISCOVERY GROWTH FUND, INC.00 551,1750Abstain
Charles Schwab468,7380 00For
Delaware/Macquarie00 379,1000Abstain
Equitable82,9990 253,9080Abstain
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 175,2800Abstain
Columbia Threadneedle155,7870 00For
Victory Capital00 139,7270Abstain
Jackson National00 136,4380Abstain
TIAA125,2900 00For
ALPS ETF Trust00 64,0900Abstain
BNY Mellon00 62,0550Abstain
ProShares00 61,7390Abstain
Principal00 60,7150Abstain
Invesco00 58,0860Abstain
American Century00 57,8980Abstain
Prudential/PGIM00 56,2230Abstain
MFS00 56,1740Abstain
Lincoln Financial00 53,1380Abstain
Thrivent00 46,4290Abstain

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

5. Election of Directors: Terry Rosen, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 67,130,968WITHHELD: 10,005,190

ARCUS BIOSCIENCES INC.’s own tally for this item (“Elect Director: Terry Rosen”): 67,130,968 for, 10,005,190 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 90,900,000 outstanding shares: 74% for, 11% withheld (85% of the company cast a for/withheld vote).

The 76 asset managers below cast 100% of the shares they voted on this item FOR (21,500,622 for, 0 against).

FOR 88%12%
FOR: 21,500,622 (88.3%)ABSTAIN: 2,842,059 (11.7%)
Largest asset managers voting on “Election of Directors: Terry Rosen, Ph.D.” at ARCUS BIOSCIENCES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,843,0230 1,3050For
BlackRock5,234,7760 00For
Vanguard4,693,4970 00For
State Street3,475,3330 50,0390For
Dimensional00 1,184,5660Abstain
AB DISCOVERY GROWTH FUND, INC.551,1750 00For
Charles Schwab468,7380 00For
Delaware/Macquarie00 379,1000Abstain
Equitable336,9070 00For
MUTUAL FUND SERIES TRUST240,0000 00For
Direxion Shares ETF Trust00 175,2800Abstain
Columbia Threadneedle155,7870 00For
Victory Capital00 139,7270Abstain
Jackson National00 136,4380Abstain
TIAA125,2900 00For
ALPS ETF Trust00 64,0900Abstain
BNY Mellon00 62,0550Abstain
ProShares00 61,7390Abstain
Principal00 60,7150Abstain
Invesco58,0860 00For
American Century00 57,8980Abstain
Prudential/PGIM00 56,2230Abstain
MFS56,1740 00For
Lincoln Financial44,4000 8,7380For
Thrivent00 46,4290Abstain

Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.

Largest ARCUS BIOSCIENCES INC. shareholders voting in 2023-2024

Ranked by the number of ARCUS BIOSCIENCES INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 90,900,000 shares outstanding at the time of that meeting.

Top ARCUS BIOSCIENCES INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 11.61%
2State Street 8.85%
3BlackRock 7.23%
4Vanguard 5.28%
5Woodline Partners LP 2.75%
6Point72 1.94%
7Dimensional 1.50%
8GEODE CAPITAL MANAGEMENT, LLC 1.27%
9AMERIPRISE FINANCIAL INC 1.16%
10AllianceBernstein 1.10%

Reported ARCUS BIOSCIENCES INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ARCUS BIOSCIENCES INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Gilead Sciences, Inc. 33.07% DEF14A
BlackRock, Inc. 11.04% DEF14A
Vanguard Group 7.29% 13F
State Street 5.40% 13F
FMR LLC 5.20% DEF14A
Terry Rosen, Ph.D. 4.17% 13D
Point72 2.11% 13F
Dimensional Fund Advisors 1.78% 13F
Morgan Stanley 1.69% 13F
Juan Carlos Jaen, Ph.D. 1.56% DEF14A

Percentages above are of 90,900,000 shares outstanding, as reported by ARCUS BIOSCIENCES INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARCUS BIOSCIENCES INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ARCUS BIOSCIENCES INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 214 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,450 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARCUS BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-06.

ARCUS BIOSCIENCES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.